TYPE 2 DIABETES MELLITUS (T2DM) is a heterogeneous
|
|
- Gordon Daniels
- 5 years ago
- Views:
Transcription
1 X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6): Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: /jc Pharmacological Treatment of Insulin Resistance at Two Different Stages in the Evolution of Type 2 Diabetes: Impact on Glucose Tolerance and -Cell Function ANNY H. XIANG, RUTH K. PETERS, SIRI L. KJOS, JOSE GOICO, CESAR OCHOA, AURA MARROQUIN, SYLVIA TAN, HOWARD N. HODIS, STANLEY P. AZEN, AND THOMAS A. BUCHANAN Departments of Preventive Medicine (A.H.X., R.K.P., S.T., H.N.H., S.P.A.), Obstetrics and Gynecology (S.L.K., T.A.B.), and Medicine (J.G., C.O., A.M., H.N.H., T.A.B.), University of Southern California Keck School of Medicine, Los Angeles, California The purpose of this study was to compare the impact of treating insulin resistance with a thiazolidinedione drug before vs. at the onset of diabetes on glucose levels and -cell function. Nondiabetic Hispanic women of Mexican or Central American descent with prior gestational diabetes mellitus (GDM) were randomized to troglitazone (early intervention), 400 mg/d, or placebo (later intervention). Women who developed diabetes were placed on open-label troglitazone. Glucose tolerance, insulin resistance, and -cell function were measured at randomization, at the diagnosis of diabetes, and 8 months post trial to determine the long-term impact of the two treatment strategies on glucose levels and -cell function. During a mean follow-up of 4.3 yr between baseline and posttrial tests, glucose tolerance (oral glucose tolerance test glucose area, P 0.04) and insulin resistance (MINMOD S I, P 0.02) worsened more in women randomized to late intervention (n 69) than to early intervention (n 57). Insulin TYPE 2 DIABETES MELLITUS (T2DM) is a heterogeneous disorder in which pancreatic -cell dysfunction that is usually progressive occurs on a background of insulin resistance (1). We found that successful treatment of insulin resistance in young, nondiabetic Hispanic women with recent GDM lowered endogenous insulin requirements and stabilized -cell function, thereby preventing T2DM for 4.5 yr (2). That observation suggests strongly that insulin resistance causes or worsens the -cell dysfunction that characterizes GDM and subsequent T2DM in Hispanic patients (3 6). Our prior observations on stabilization of -cell function (2) were made in women who had either normal or impaired glucose tolerance at the initiation of treatment. The present analysis was conducted to compare that early treatment strategy to one in which treatment is withheld until the onset of T2DM. Abbreviations: AIRg, Acute insulin response to iv glucose; DI, disposition index; GDM, gestational diabetes mellitus; ivgtt, iv glucose tolerance test; Kg, glucose disappearance; ogtt, oral glucose tolerance test; S I, insulin sensitivity ; T2DM, type 2 diabetes mellitus; TRIPOD, Troglitazone in Prevention of Diabetes (study); UKPDS, United Kingdom Prospective Diabetes Study. JCEM is published monthly by The Endocrine Society ( endo-society.org), the foremost professional society serving the endocrine community. secretion (acute insulin response in the iv glucose tolerance test, P 0.09) and -cell compensation for insulin resistance (disposition index, P 0.07) also tended to worsen more in the late intervention group. Among women in the late intervention group who developed diabetes, oral glucose tolerance test glucose area (P ) and -cell function (P < 0.04) deteriorated significantly during development of diabetes on placebo and then did not change significantly (P > 0.50) during treatment with troglitazone and posttreatment washout. In high-risk Hispanic women, amelioration of insulin resistance can stabilize glycemia at the time diabetes develops. These findings highlight the role of insulin resistance in the genesis of progressive -cell dysfunction during the evolution of type 2 diabetes. (J Clin Endocrinol Metab 89: , 2004) Subjects and Methods Subjects and design The Troglitazone in Prevention of Diabetes (TRIPOD) study was designed to address the impact of troglitazone treatment on pancreatic -cell function and glucose levels in Hispanic women with prior GDM before the development of diabetes and also at the onset of diabetes. Descriptions of the design of the study and the results of the primary blinded trial (treatment before diabetes) have been published previously (2, 7). Briefly, between August 1995 and May 1998, 266 nondiabetic women of Mexican or Central American descent who were at least 18 yr old, with a history of GDM in the prior 4 yr and a total glucose area on a 75-g oral glucose tolerance test (ogtt) above the median for women with GDM (8), were randomly assigned to receive placebo or 400 mg of troglitazone daily in a double-blind fashion. Fasting plasma glucose was measured every 3 months, and 75-g ogtts were performed annually to test for diabetes (1). Women continued on their assigned medication until they developed diabetes, dropped out of the trial, or reached the end of the trial, when final on-trial testing for diabetes was performed. Women who developed diabetes while on blinded treatment before the end of the trial were offered treatment with troglitazone until they dropped out, reached the end of the trial, or developed a hemoglobin A 1C concentration, measured every 3 months from the diagnosis of diabetes onward, that was more than 7%. Thus, women initially assigned to troglitazone were given active drug before they developed diabetes (early intervention strategy). Women initially assigned to placebo were given active drug if and when they were first found to have diabetes during frequent testing for the disease (late intervention strategy). The study was designed to end in August Troglitazone was withdrawn from clinical use in March Subjects active in the trial at that time were asked to return for a final on-trial ogtt and then for a posttrial 2846
2 Xiang et al. Treatment of Insulin Resistance J Clin Endocrinol Metab, June 2004, 89(6): ogtt 8 months after stopping study medications. Frequently sampled ivgtts were performed at randomization, three months later, 3 months after entering the open label phase of the study for patients who did so, and 8 months post trial. All participants gave written informed consent for participation in the IRB-approved study. IRB approval and informed consent were updated during the study as information about potentially serious heptotoxicity of troglitazone became available. No serious hepatotoxicity was observed during the TRIPOD study. A summary of the frequency of reversible transaminase elevations appears in the description of the blinded trial (2). Clinical testing protocols ogtts and ivgtts were initiated between h, after an 8- to 12-h overnight fast. For ogtts, subjects drank 75 g dextrose. Venous blood was sampled from an indwelling catheter before and 30, 60, 90, and 120 min after the dextrose ingestion. For ivgtts, dextrose (300 mg/kg body weight) was injected into an antecubital vein. Tolbutamide (125 mg/m 2 body surface area) was injected 20 min later. Twenty-two arterialized venous blood samples were drawn and placed on ice before and up to 240 min after the dextrose injection. Plasma was separated within 20 min and stored at 80 C. Laboratory methods Glucose was measured by glucose oxidase (Beckman Glucose Analyzer II, Beckman Instruments, Brea, CA). Insulin was measured by a RIA (Linco Research, St. Charles, MO) that provided less than 0.2% cross-reactivity with proinsulin. Data analysis Whole-body insulin sensitivity (S I ) was calculated from ivgtts using the Bergman minimal model (9). Glucose disappearance (Kg) during ivgtts was calculated as 100 times the fractional Kg rate between 10 and 40 min after the glucose injection. Areas under glucose and insulin curves were calculated using the trapezoid rule. The acute insulin response to iv glucose (AIRg; the incremental insulin area between 0 10 min after the glucose injection) was used as a sensitive measure of -cell well-being (10), reflecting a combination of -cell mass (11) and function. (12). The product of AIRg and S I (the disposition index, DI) was used as a measure of the ability of -cells to compensate for insulin resistance (13 15). Baseline characteristics were compared between groups using twogroup t tests for continuous variables and 2 or Fisher s exact tests for categorical variables. For nonnormally distributed variables, such as insulin, insulin area, S I, and first-phase insulin response, natural logtransformation was used before t tests. Square root transformation was used for the DI. Means and sds are presented in the original measurement scales. Changes in variables over time were assessed as actual changes, percent changes, and rates of change, because subjects had different lengths of follow-up. These analyses led to similar conclusions, and only absolute changes are presented. Absolute changes were normally distributed and analyzed using parametric t tests. Data are presented as means sd in tables and text and as means se in figures. All statistical tests were two-sided, and statistical significance was set at P 0.05 for presentation of results. Blinded trial Results As reported previously (2), 236 women returned for at least one follow-up visit, 122 randomized to placebo (late intervention) and 114 randomized to troglitazone (early intervention). Annual dropout rates were 13.4% and 16.3%, respectively (P 0.44). Pill compliance rates, based on pill counts at each follow-up visit, were 87 10% and 85 16%, respectively (P 0.30). Average annual incidence rates of diabetes during the blinded trial were 12.1% and 5.4%, respectively (P 0.009). Comparison of early vs. later intervention strategies One hundred twenty-six women completed the trial and returned for posttrial testing, providing the full set of data required for inclusion in this report. Of the 110 women who ended participation before the final posttrial tests, three developed HbA 1c more than 7% during open-label treatment with troglitazone and were referred for management of their diabetes (two in the late and one in the early intervention group), and one (in the late intervention group) was pregnant at the time of posttrial testing. The remaining 106 women were lost to follow-up during the trial or posttrial period. At baseline, none of the following variables differed significantly between women who completed all required testing and women who ended their participation before posttrial testing in the cohort overall or within groups assigned to late intervention or early intervention: age, body mass index, ogtt glucose and insulin areas, ivgtt S I, AIRg, and DI (all P 0.18). Of the 126 women who completed the trial and posttrial testing, 69 had been randomized to late intervention, and 57 had been randomized to early intervention. Baseline characteristics were similar in the two groups (Table 1). Posttrial testing was completed at medians of 7.9 and 7.6 months after study medications were stopped in late and early intervention groups, respectively. These posttrial intervals corresponded to means of 4.3 and 4.4 yr after randomization in each group (Table 2). Glucose and insulin values during ogtts rose significantly between baseline and posttrial testing in the late intervention group but remained stable in the early intervention group (Fig. 1). Changes from baseline for other variables appear in Table 2. Weight increased significantly in both groups and slightly, but not significantly, more in the early intervention group. ogtt glucose area rose significantly, and S I fell significantly in the late intervention group, whereas neither variable changed significantly in the early intervention group. As a result, there were significant differences between groups in the changes in these two variables. AIRg, DI, and Kg fell significantly in the late intervention group. These measures fell less, and not significantly, in the early intervention group. Differences between groups in changes in AIRg, DI, and Kg were of borderline statistical significance (P ). Thus, assignment to the early intervention strategy was associated with significantly less worsening of glucose tolerance and insulin resistance and somewhat greater preservation of -cell function, compared with assignment to the late intervention strategy. Fifty-five of the 57 women in the early intervention group had ivgtts 3 months after starting blinded troglitazone. Thirteen of them had a change in S I that was less than min 1 / U/ml ( min 1 /pmol/liter) at 3-months (nonresponders, as defined in the description of the TRIPOD blinded trial (2). The other 42 women had a greater increase in S I (troglitazone responders (2). The ogtt glucose area was essentially unchanged in the 4.4 yr between baseline and posttrial testing in responders [ mg/dl min ( mmol/liter min), P 0.75] but rose significantly during the 4.3 yr between tests in nonresponders [ mg/dl min ( mmol/liter min), P 0.002]. The DI during the same interval was unchanged in the responders (1 845, P 0.99) but fell in the nonresponders ( , P 0.07). Thus, women who failed to respond to the primary insulin-sensitizing effect of troglitazone accounted for the small rise in glucose levels and small loss of -cell function that occurred in the early intervention group. Impact of troglitazone in women who developed diabetes Of the 126 women who completed the trial and posttrial testing, 23 in the late intervention group and 13 in the early intervention group developed diabetes and went on to open label treatment with troglitazone during the trial. Characteristics at study entry, at the diagnosis of diabetes, and at posttrial testing for these 36 women appear in Table 3 and Fig. 2. In the late intervention group (n 23), the average time from enrollment to development of diabetes was yr. The average duration of treatment with troglitazone plus posttrial washout was yr. Weight increased during both periods, although somewhat less during active treatment plus washout. Glucose areas during ogtts rose during the development of diabetes and then remained essentially stable during troglitazone treatment and washout. S I fell progressively across the two periods but not significantly in either period. AIRg fell in the presence of worsening insulin resistance during the development of diabetes and then increased slightly in the presence of additional insulin resistance during troglitazone treatment and washout. As a result, the DI fell during the development of diabetes, then stabilized during tro-
3 2848 J Clin Endocrinol Metab, June 2004, 89(6): Xiang et al. Treatment of Insulin Resistance TABLE 1. Baseline characteristics of women who completed the trial and returned for posttrial testing a Variable Intervention strategy Late (n 69) Early (n 57) P-value b Age (yr) 34.3 (6.6) 35.4 (6.5) 0.34 Body mass index (kg/m 2 ) 29.6 (4.6) 30.1 (5.3) 0.59 Waist:hip circumference ratio 0.86 (0.05) 0.85 (0.07) 0.33 ogtt Fasting glucose (mg/dl) 98.8 (9.6) 99.3 (10.0) h glucose (24.1) (23.8) 0.40 Total glucose area (mg/dl min 10 3 ) c 18.8 (2.0) 19.1 (2.2) 0.38 Impaired glucose tolerance d 78% 75% 0.83 Fasting insulin ( U/ml) 14.1 (6.5) 14.5 (7.4) 0.72 Total insulin area ( U/ml min) c 8791 (5166) 7975 (4018) 0.33 ivgtt e S I (min 1 / U/ml 10 4 ) f 2.02 (1.42) 2.17 (1.30) 0.53 AIRg ( U/ml min) g 392 (334) 329 (265) 0.25 DI (S I AIRg) h 873 (663) 804 (626) 0.55 Kg (min 1 100) i 1.49 (0.40) 1.42 (0.40) 0.39 To convert values for glucose to millimoles per liter, multiply by To convert values for insulin to picomoles per liter, multiply by 6.0. a Fraction of women in treatment group or mean (SD) in original scale except insulin, insulin area, S I and AIRg (geometric means), and DI (squared means after square root transformation). b By two-group t test for means, 2 or Fisher s exact test for proportions. c Calculated by trapezoid method using data from entire duration of test. d Plasma glucose mg/dl 2 h after 75-g oral glucose load. e ivgtt, as described in Subjects and Methods. f Calculated by the Bergman minimal model (9). g Incremental insulin area between 0 and 10 min after the glucose injection. h A measure of -cell compensation for insulin resistance. i 100 Fractional Kg rate min after glucose injection. TABLE 2. Changes between baseline and posttrial tests a Variable Late (n 69) Intervention strategy Within-group Early (n 57) Within-group P-value b P-value b Between-group P-value c Age (yr since randomization) 4.3 (0.8) 4.4 (0.7) 0.77 Weight (kg) 3.0 (5.4) (4.1) ogtt glucose area (mg/dl min 10 3 ) 1.8 (4.4) (3.5) S I (min 1 / U/ml 10 4 ) d 0.60 (1.69) (1.66) AIRg ( U/ml min) d 197 (491) (362) DI (S I AIRg) d 344 (642) (788) Kg (min 1 100) d 0.18 (0.37) (0.41) To convert values for glucose to millimoles per liter, multiply by To convert values for insulin to picomoles per liter, multiply by 6.0. a Mean (SD) in original measurement scales, without transformation. b By paired t test comparing baseline and posttrial values within groups. c By two groups t test comparing changes from baseline between groups. d As defined in Table 1. glitazone treatment and washout. In the early intervention group (n 13), the average times from enrollment to development of diabetes ( yr) and the duration of treatment with open-label troglitazone plus posttrial washout ( yr) were similar to the analogous intervals in the late intervention group. Weight increased significantly during development of diabetes on blinded medication and then decreased very slightly during open-label treatment and washout. Glucose areas from ogtts rose during both periods, but the rise was statistically significant only during development of diabetes on blinded medication. S I did not change significantly during either period or consistently across periods. AIRg and the DI fell during both periods, but the reductions within periods were not statistically significant in this small subgroup of women. Eighteen of the 23 women who participated in the late intervention by receiving open-label troglitazone after developing diabetes had an IVGTT 3 months after starting open-label drug. Twelve were responders to the insulin-sensitizing effect of troglitazone, and six were nonresponders, as defined above (2). The responders had better preservation of -cell function than the nonresponders. Specifically, in the 2.2 yr of troglitazone treatment and washout, the DI rose in the responders and fell in the nonresponders (P 0.04 between groups). These changes in -cell function were associated with changes in ogtt glucose areas in the responders [fall of mg/dl min ( mmol/liter min)] and nonresponders [rise of mg/dl min ( mmol/liter min)] that were directionally opposite but not significantly different (P 0.58). Discussion We report two main observations from the early vs. late intervention component of the TRIPOD study. First, early treatment designed to ameliorate insulin resistance before the diagnosis of diabetes was superior to later intervention at the initial diagnosis of diabetes regarding stabilization of glucose levels and insulin resistance and tended to be superior for preservation of pancreatic -cell function. Second,
4 Xiang et al. Treatment of Insulin Resistance J Clin Endocrinol Metab, June 2004, 89(6): FIG. 1. Plasma glucose and insulin concentrations during 75-g ogtts at baseline (closed symbols) and posttrial testing (open symbols) in women who participated in the entire trial and returned for posttrial testing after randomization to late intervention strategy (left panels, n 69) or early intervention strategy (right panels, n 57), as defined in Subjects and Methods. *,P 0.05; **, P 0.01 vs. baseline in the same treatment strategy. To convert values for glucose to millimoles per liter, multiply by To convert values for insulin to picomoles per liter, multiply by 6.0. the loss of -cell function that characterized progression to diabetes during placebo treatment was arrested when treatment with troglitazone was initiated at the onset of diabetes. Stabilization of -cell function was limited to women whose S I improved when they received troglitazone. These findings reveal that -cell function can be preserved by treatment of insulin resistance not only before the onset of diabetes, as we reported previously (2), but also when diabetes first develops. Delaying treatment until diabetes develops is accompanied by a rise in glucose levels and a loss of -cell function that cannot be reversed by slightly more than 2 years of troglitazone treatment. Whether the additional hyperglycemia and loss of -cell function are important to long-term health remains to be determined. The present findings compliment our prior analysis of the blinded component of the TRIPOD trial (2). That analysis revealed a significant reduction in the incidence of diabetes, along with preservation of -cell function in high-risk nondiabetic women who were randomized to troglitazone compared with placebo. The present results indicate that a similar effect can be achieved at a somewhat later stage, soon after glucose concentrations reach the level of diabetes. Our findings contrast with the common observation that T2DM is a progressive disease in patients who present with more advanced diabetes. For example, in the United Kingdom Prospective Diabetes Study (UKPDS), patients who presented with diabetic symptoms and complications (16) manifested rising glycemia (17 19) and falling -cell function (19) during treatment with diet, sulfonylurea drugs, metformin, and/or insulin. The precise reason for the different patterns of -cell function between the UKPDS and the present study is not known. One possibility is that thiazolidinedione drugs, which were not used in the UKPDS, have a unique effect to stabilize -cell function that was not provided by the treatments that were used in the UKPDS. In our analysis of the blinded component of the TRIPOD study, we found no evidence for a direct effect of troglitazone on -cells. Rather, protection from diabetes appeared to be mediated by a reduction in endogenous insulin requirements ( -cell rest) that was achieved, to varying degrees, by amelioration of insulin resistance (2). Given their large effect to ameliorate insulin resistance, thiazolidinediones may be more effective at mediating -cell rest than are treatments that were used in the UKPDS. Alternatively, delaying treatment of insulin resistance until patients have developed clinically apparent T2DM, as was done in the UKPDS and is common in clinical practice, could be inferior to earlier treatment, to the extent that reduced -cell mass at later stages (20) makes it progressively difficult to rest individual -cells. Finally, the duration of observation after development of diabetes in the TABLE 3. Characteristics at baseline, diagnosis of diabetes, and posttrial testing in women who developed diabetes during blinded treatment, switched to open-label troglitazone treatment, and returned for posttrial testing a Variable Baseline Diagnosis of diabetes Post trial P b P c Late intervention group (n 23) Age (yr) 34.4 (6.4) 36.4 (6.8) 38.7 (6.6) Weight (kg) 71.2 (13.7) 73.6 (13.0) 75.1 (14.8) OGTT glucose area (mg/dl min 10 3 ) d 20.3 (2.3) 23.2 (2.6) 23.1 (4.2) S I (min 1 / U/ml 10 4 ) d 1.63 (0.88) 1.48 (1.00) 1.23 (1.21) AIRg ( U/ml min) d 245 (236) 89 (244) 120 (145) DI (S I AIRg) d 517 (572) 335 (478) 318 (528) Early intervention group (n 13) Age (yr) 36.5 (4.7) 38.5 (4.9) 40.8 (4.7) Weight (kg) 74.3 (10.4) 78.9 (11.3) 78.2 (11.1) OGTT glucose area (mg/dl min 10 3 ) d 21.1 (1.8) 23.4 (2.7) 24.9 (4.2) S I (min 1 / U/ml 10 4 ) d 2.02 (0.95) 2.46 (1.73) 2.25 (1.30) AIRg ( U/ml min) d 182 (195) 125 (134) 80 (128) DI (S I AIRg) d 468 (511) 361 (377) 241 (464) To convert values for glucose to millimoles per liter, multiply by To convert values for insulin to picomoles per liter, multiply by 6.0. a Mean (SD) in original scale except for insulin, insulin area, S I and AIRg (geometric means), and DI (squared mean after square root transformation). b For change from baseline to development of diabetes (paired t test). c For change from diagnosis of diabetes to posttrial test (paired t test). d As defined in Table 1.
5 2850 J Clin Endocrinol Metab, June 2004, 89(6): Xiang et al. Treatment of Insulin Resistance FIG. 2. DI, a measure of -cell compensation for insulin resistance, in women from late (left panel, n 23) and early (right panel, n 13) intervention groups who developed diabetes on blinded medication (blinded placebo, blinded trog.) and then participated in open-label troglitazone treatment (open trog.) and posttrial testing (post trial). P-values are for paired t tests between successive time points. present study was relatively short (approximately 2 yr), whereas -cell deterioration in the UKPDS was observed over a longer period of time. Whether the stabilization of -cell function that we observed with troglitazone treatment at the onset of diabetes can be sustained for prolonged periods of time remains to be determined. Women who developed diabetes while taking blinded troglitazone did not appear to benefit from additional treatment with open-label troglitazone. Their glucose levels rose and their -cell function fell during development of diabetes on blinded drug and continued to do so when they were switched to open-label drug. These results are not surprising, because knowledge of treatment rather than the treatment itself was changed when subjects switched from blinded to open-label troglitazone. Nonetheless, the pattern of -cell function displayed by those women (Fig. 2, right panel) is important in that it demonstrates that continued loss of -cell function is the natural progression after diabetes develops in the absence of effective treatment. Against that background, the stabilization in glucose levels and -cell function that occurred in the late intervention group when they were placed on troglitazone at the onset of diabetes can be attributed with confidence to the effect of the drug. In the TRIPOD blinded trial (2), women who failed to increase S I when placed on troglitazone did benefit from the drug. The same general pattern was observed in the present analysis, although sample sizes and statistical power were lower than in the blinded phase of the study. Nonetheless, we observed that women in the early intervention group who failed to respond to the insulin-sensitizing effects of troglitazone lost -cell function, whereas responders had stable function for more than 4 yr. Similarly, nonresponders in the late intervention group continued to lose -cell function after being placed on troglitazone, whereas responders had a small increase in function 2.4 yr later. These findings, combined with the more robust analysis from the blinded phase of TRIPOD, provide strong evidence for the importance of treating insulin resistance to preserve -cell function. The present report indicates that the effect can be achieved at the time diabetes first develops. We focused this report on women who had measures of glucose tolerance, insulin resistance, and -cell function at baseline and after the posttrial washout period. This approach allowed us to determine changes in relevant variables in the absence of acute drug effects. It also resulted in the exclusion of data from a relatively large fraction of women who ended their participation before posttrial testing. The exclusions did not appear to be systematically biased regarding crucial metabolic parameters, because those parameters were similar at baseline in women who dropped out before posttrial tests and women who provided posttrial data for this report. Thus, our approach provided a valid assessment of the chronic effects of treatment on the biology of T2DM. The clinical relevance of our findings is limited by two facts. First, troglitazone is no longer available for clinical use. As detailed in our publication of the results of the blinded component of the TRIPOD study (2), the protective effect of troglitazone appeared to be mediated by a reduction in endogenous insulin requirements mediated by amelioration of insulin resistance. Thus, other methods for reducing insulin resistance, including weight loss and treatment with other insulin-sensitizing compounds, should have analogous beneficial effects. Such effects remain to be proven but could have contributed to protection from diabetes observed in the lifestyle intervention arms of the Diabetes Prevention Program (21) and the Diabetes Prevention Study (22), as well as the protection observed in the metformin arm of the former study (21). The second limitation is the tight ethnic focus of the TRIPOD study. All subjects were Hispanic American of Mexican or Central American ancestry. Whether amelioration of insulin resistance in other ethnic groups can preserve -cell function is unknown, although the relatively uniform effects of exercise and weight loss to reduce the incidence of diabetes in different ethnic groups in the Diabetes Prevention Program (21) suggests a generalized beneficial effect. In summary, amelioration of insulin resistance with troglitazone in Hispanic women with previous GDM stabilized glycemia and -cell function before the onset of diabetes and at the time diabetes was first detected by frequent testing. The cost of waiting until diabetes developed was some loss of glucose tolerance and -cell function that could not be recovered by 2 yr of treatment with troglitazone. When considered in light of the usually progressive course of hyperglycemia and declining -cell function in T2DM (17 19), our findings support a focus on prevention and early treatment of the disease through amelioration of insulin resistance to preserve pancreatic -cell function. Acknowledgments The authors thank Susie Nakao, Carmen Martinez, and the staff of the General Clinical Research Center for assistance with metabolic studies; the TRIPOD Data Safety Monitoring Committee for their guidance in the
6 Xiang et al. Treatment of Insulin Resistance J Clin Endocrinol Metab, June 2004, 89(6): conduct of the study; and Lilit Zeberians, Mike Salce, and Jay Sisson for performance of assays. Received November 24, Accepted March 9, Address all correspondence and requests for reprints to: Thomas A. Buchanan, M.D., Room 6602 GNH, 1200 North State Street, Los Angeles, California buchanan@usc.edu. This work was supported by Research Grant PD , Parke- Davis Pharmaceutical Research; M01-RR-43 from the General Clinical Research Branch, National Center for Research Resources, National Institutes of Health (NIH); Clinical Research Award from the American Diabetes Association; and R01-DK from the National Institute of Diabetes and Digestive and Kidney Diseases, NIH. References 1. American Diabetes Association 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP 2002 Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: Buchanan TA, Metzger BE, Freinkel N, Bergman RN 1990 Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 162: Xiang AH, Peters RK, Trigo E, Kjos SL, Lee WP, Buchanan TA 1999 Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes mellitus. Diabetes 48: Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK 1999 Antepartum predictors of the development of type 2 diabetes in Latino women months after pregnancies complicated by gestational diabetes. Diabetes 48: Buchanan TA, Xiang A, Kjos SL 1998 Gestational diabetes mellitus: antepartum metabolic characteristics that predict postpartum glucose intolerance and type 2 diabetes. Diabetes 47: Azen SP, Peters R, Berkowitz K, Kjos S, Xiang A, Buchanan TA 1998 TRIPOD: a randomized placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19: Kjos SL, Peters RK, Xiang A, Henry OA, Montoro MN, Buchanan TA 1995 Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. Diabetes 44: Pacini G, Bergman RN 1986 MINMOD, a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23: Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte Jr D 1976 Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42: Kjems LL, Kirby BM, Welsh EM, Veldhuis JD, Straume M, McIntyre SS, Yang D, Lefebvre P, Butler PC 2001 Decrease in -cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50: Vague P, Moulin J-P 1982 The defective glucose sensitivity of the B-cell in noninsulin dependent diabetes: improvement after twenty hours of normoglycemia. Metabolism 31: Bergman RN 1989 Toward physiological understanding of glucose tolerance. Minimal model approach. Diabetes 38: Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte Jr D 1993 Quantification of the relationship between insulin sensitivity and B-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42: Buchanan TA, Xiang AH, Peters RK, 2000 Response of pancreatic B-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 49: Colagiuri S, Cull CA, Holman RR, UKPDS Study Group 2003 Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? Diabetes Care 25: UKPDS Study Group 1998 Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352: UKPDS Study Group 1998 Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352: UKPDS Study Group 1995 Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 44: Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC 2003 B-cell deficit and increased B-cell apoptosis in humans with type 2 diabetes. Diabetes 52: Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne- Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: JCEM is published monthly by The Endocrine Society ( the foremost professional society serving the endocrine community.
4 Department of Preventive Medicine, University of Southern California Keck
Preservation of Pancreatic -Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women Thomas A. Buchanan, 1,2,3 Anny H. Xiang, 3,4 Ruth
More informationIn the past 6 years, several randomized controlled
Perspectives in Diabetes (How) Can We Prevent Type 2 Diabetes? Thomas A. Buchanan In the past 6 years, several randomized controlled trials have been conducted to test the impact of behavioral and pharmacological
More informationThe Efficacy and Cost of Alternative Strategies for Systematic Screening for Type 2 Diabetes in the U.S. Population Years of Age
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E The Efficacy and Cost of Alternative Strategies for Systematic Screening for Type 2 Diabetes in the U.S. Population 45 74
More informationThe oral meal or oral glucose tolerance test. Original Article Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol
Original Article Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol Minimal Model Assessment of -Cell Responsivity and Insulin Sensitivity in Nondiabetic Individuals Chiara Dalla Man,
More informationLong-Acting Injectable Progestin Contraception and Risk of Type 2 Diabetes in Latino Women With Prior Gestational Diabetes Mellitus 2,3
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Long-Acting Injectable Progestin Contraception and Risk of Type 2 Diabetes in Latino Women With Prior Gestational Diabetes Mellitus ANNY
More informationGLUCOSE TOLERANCE STATUS is traditionally defined
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):747 754 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-1258 The Normal Glucose Tolerance Continuum
More informationHypertension, a common disorder
Pathophysiology/Complications O R I G I N A L A R T I C L E Insulin Resistance and Preeclampsia in Gestational Diabetes Mellitus MARTIN N. MONTORO, MD 1,2 SIRI L. KJOS, MD 1 MARY CHANDLER, MD 3 3 RUTH
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationSafety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus Journal Club (May 2013) Sara Al-Sharhan, Pharm D intern-
More informationGestational Diabetes in Korea: Incidence and Risk Factors of Diabetes in Women with Previous Gestational Diabetes
Review doi: 10.4093/dmj.2011.35.1.1 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Gestational Diabetes in Korea: Incidence and Risk Factors of Diabetes in Women with
More informationGestational Diabetes. Gestational Diabetes:
Gestational Diabetes Detection and Management Steven Gabbe, MD The Ohio State University Medical Center Gestational Diabetes: Detection and Management Learning Objectives: At the conclusion of this presentation,
More informationHigh Calorie Intake Is Associated With Worsening Insulin Resistance and b-cellfunctionin Hispanic Women After Gestational Diabetes Mellitus
3294 Diabetes Care Volume 37, December 2014 High Calorie Intake Is Associated With Worsening Insulin Resistance and b-cellfunctionin Hispanic Women After Gestational Diabetes Mellitus Zhanghua Chen, 1
More informationEarly Detection of Insulin Sensitivity and -Cell Function with Simple Tests Indicates Future Derangements in Late Pregnancy
ORIGINAL Endocrine ARTICLE Care Early Detection of Insulin Sensitivity and -Cell Function with Simple Tests Indicates Future Derangements in Late Pregnancy A. Lapolla, M. G. Dalfrà, G. Mello, E. Parretti,
More informationSubsequent Pregnancy After Gestational Diabetes Mellitus. Frequency and risk factors for recurrence in Korean women
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Subsequent Pregnancy After Gestational Diabetes Mellitus Frequency and risk factors for recurrence in Korean women SOO HEON KWAK, MD 1 HAE
More informationCurrent Trends in Diagnosis and Management of Gestational Diabetes
Current Trends in Diagnosis and Management of Gestational Diabetes Shreela Mishra, MD Assistant Clinical Professor UCSF Fresno Medical Education Program 2/2/2019 Disclosures No disclosures 2/2/19 Objectives
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationPhysical activity and the metabolic syndrome in elderly German men and women: Results from the population based KORA survey
Diabetes Care Publish Ahead of Print, published online December 15, 2008 Physical activity and the metabolic syndrome in elderly German men and women: Results from the population based KORA survey Valerie
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationGestational Diabetes and the Incidence
Reviews/Commentaries/Position R E V I E W A R T I C L E Statements Gestational Diabetes and the Incidence of Type 2 Diabetes A systematic review CATHERINE KIM, MD, MPH 1 KATHERINE M. NEWTON, PHD 2 ROBERT
More information/01/$03.00/0 The Journal of Clinical Endocrinology & Metabolism 86(12): Copyright 2001 by The Endocrine Society
0013-7227/01/$03.00/0 The Journal of Clinical Endocrinology & Metabolism 86(12):5824 5829 Printed in U.S.A. Copyright 2001 by The Endocrine Society Importance of Early Phase Insulin Secretion to Intravenous
More informationPrevention of diabetes and its associated
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E Identifying Individuals at High Risk for Diabetes The Atherosclerosis Risk in Communities study MARIA INÊS SCHMIDT,
More information28 Regulation of Fasting and Post-
28 Regulation of Fasting and Post- Prandial Glucose Metabolism Keywords: Type 2 Diabetes, endogenous glucose production, splanchnic glucose uptake, gluconeo-genesis, glycogenolysis, glucose effectiveness.
More informationRacial and ethnic disparities in diabetes risk after gestational diabetes mellitus
Diabetologia (2011) 54:3016 3021 DOI 10.1007/s00125-011-2330-2 ARTICLE Racial and ethnic disparities in diabetes risk after gestational diabetes mellitus A. H. Xiang & B. H. Li & M. H. Black & D. A. Sacks
More informationGestational diabetes mellitus
Gestational diabetes mellitus Thomas A. Buchanan, Anny H. Xiang J Clin Invest. 2005;115(3):485-491. https://doi.org/10.1172/jci24531. Science in Medicine Gestational diabetes mellitus (GDM) is defined
More informationA46-yr-old female is referred to you for an abnormal fasting
SPECIAL FEATURE Approach to the Patient Approach to the Patient with Prediabetes Vanita R. Aroda and Robert Ratner Med Star Clinical Research Center, Washington, D.C. 20003 Prediabetes consists of impaired
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationA CLINICAL STUDY OF GESTATIONAL DIABETES MELLITUS IN A TEACHING HOSPITAL IN KERALA Baiju Sam Jacob 1, Girija Devi K 2, V.
A CLINICAL STUDY OF GESTATIONAL DIABETES MELLITUS IN A TEACHING HOSPITAL IN KERALA Baiju Sam Jacob 1, Girija Devi K 2, V. Baby Paul 3 HOW TO CITE THIS ARTICLE: Baiju Sam Jacob, Girija Devi K, V. Baby Paul.
More informationAuthor's response to reviews
Author's response to reviews Title: Prevention of Type 2 Diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project Authors:
More informationTreating Postprandial Hyperglycemia Does Not Appear to Delay Progression of Early Type 2 Diabetes
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Treating Postprandial Hyperglycemia Does Not Appear to Delay Progression of Early Type 2 Diabetes The Early Diabetes Intervention Program
More informationTHE ANALYZATION OF TIME-BLOOD GLUCOSE CURVE DURING ORAL GLUCOSE TOLERANCE TEST IN PREGNANT WOMEN
Acta Transitional Medicine An International Scientific Journal ISSN: 2521-8662 Volume 1 Issue 2 pp.10-14 June 2018 THE ANALYZATION OF TIME-BLOOD GLUCOSE CURVE DURING ORAL GLUCOSE TOLERANCE TEST IN PREGNANT
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDecreased -Cell Function in Overweight Latino Children With Impaired Fasting Glucose
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E Decreased -Cell Function in Overweight Latino Children With Impaired Fasting Glucose MARC J. WEIGENSBERG, MD 1
More informationObjectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT
Diabetes- The Real Cost of Sugar By Ruth Nekonchuk RD CDE LMNT Objectives To explain diabetes To explain the risks of diabetes To enumerate the cost of diabetes to our country To enumerate the cost of
More informationDiabetes Related Disclosures
Diabetes Related Disclosures Speakers Bureau Amylin Boehringer Ingelheim Eli Lilly Takeda Classification of Diabetes Diabetes Care January 2011 vol. 34 no. Supplement 1 S11-S61 Type 1 Diabetes Mellitus
More informationTYPE 2 DIABETES MELLITUS is a common, multifactorial
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2019 2023 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-031325 The G-250A Promoter Polymorphism
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationBPA exposure during pregnancy: risk for gestational diabetes and diabetes following pregnancy
BPA exposure during pregnancy: risk for gestational diabetes and diabetes following pregnancy Paloma Alonso-Magdalena Applied Biology Department and CIBERDEM, Miguel Hernández University, Elche, Spain
More informationThe enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans
The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Seoul National University College of Medicine Plasma glucose
More informationAssociations among Body Mass Index, Insulin Resistance, and Pancreatic ß-Cell Function in Korean Patients with New- Onset Type 2 Diabetes
ORIGINAL ARTICLE korean j intern med 2012;27:66-71 pissn 1226-3303 eissn 2005-6648 Associations among Body Mass Index, Insulin Resistance, and Pancreatic ß-Cell Function in Korean Patients with New- Onset
More informationPREVIOUS STUDIES IN children have highlighted the
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(1):207 212 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-031402 Impaired Glucose Tolerance and
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationInsulin release, insulin sensitivity, and glucose intolerance (early diabetes/pathogenesis)
Proc. Natl. Acad. Sci. USA Vol. 77, No. 12, pp. 7425-7429, December 1980 Medical Sciences nsulin release, insulin sensitivity, and glucose intolerance (early diabetes/pathogenesis) SUAD EFENDt, ALEXANDRE
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationIt s Never Too Early To Prevent Diabetes: The Lasting Impact of Gestational Diabetes on Mothers and Children
It s Never Too Early To Prevent Diabetes: The Lasting Impact of Gestational Diabetes on Mothers and Children Robert Ratner, M.D., F.A.C.P. Vice President for Scientific Affairs, Medstar Research Institute
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationGestational diabetes mellitus (GDM)
O R I G I N A L A R T I C L E What Is Gestational Diabetes? THOMAS A. BUCHANAN, MD 1 ANNY XIANG, PHD 2 Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first recognition
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationDiabetes Care 24:89 94, 2000
Pathophysiology/Complications O R I G I N A L A R T I C L E Insulin Resistance and Insulin Secretory Dysfunction Are Independent Predictors of Worsening of Glucose Tolerance During Each Stage of Type 2
More informationIT IS WELL recognized that in subjects with noninsulin
0021-972X/98/$03.00/0 Vol. 83, No. 2 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Disproportionately Elevated Proinsulin Levels Reflect the
More informationIs Reduced First-Phase Insulin Release the Earliest Detectable Abnormality in Individuals Destined to Develop Type 2 Diabetes?
Is Reduced First-Phase Insulin Release the Earliest Detectable Abnormality in Individuals Destined to Develop Type 2 Diabetes? John E. Gerich Insulin is released from the pancreas in a biphasic manner
More informationG enetic and environmental factors
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Insulin Secretion and Its Determinants in the Progression of Impaired Glucose TolerancetoType2DiabetesinImpaired Glucose-Tolerant
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationMuscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test
Pathophysiology/Complications O R I G I N A L A R T I C L E Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test MUHAMMAD A. ABDUL-GHANI, MD, PHD MASAFUMI MATSUDA, MD
More informationTreating Type 2 Diabetes by Treating Obesity. Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition
Treating Type 2 Diabetes by Treating Obesity Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition 2 Center Stage Obesity is currently an epidemic in the United States, with
More informationGlucagon secretion in relation to insulin sensitivity in healthy subjects
Diabetologia (2006) 49: 117 122 DOI 10.1007/s00125-005-0056-8 ARTICLE B. Ahrén Glucagon secretion in relation to insulin sensitivity in healthy subjects Received: 4 July 2005 / Accepted: 12 September 2005
More informationImpaired Glucose Tolerance
Page 1 of 6 Impaired Glucose Tolerance If you have impaired glucose tolerance, your blood glucose is raised beyond the normal range but it is not so high that you have diabetes. However, if you have impaired
More informationImplementing Type 2 Diabetes Prevention Programmes
Implementing Type 2 Diabetes Prevention Programmes Jaakko Tuomilehto Department of Public Health University of Helsinki Helsinki, Finland FIN-D2D Survey 2004 Prevalence of previously diagnosed and screen-detected
More informationWhy do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?
What is Diabetes? Diabetes 101 Ginny Burns RN MEd CDE Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action
More informationInflammation & Type 2 Diabetes Prof. Marc Y. Donath
Inflammation & Type 2 Diabetes 1, MD Chief Endocrinology, Diabetes & Metabolism University Hospital Basel Petersgraben 4 CH-431 Basel, Switzerland MDonath@uhbs.ch Innate immunity as a sensor of metabolic
More informationAsian Journal of Medical and Biological Research ISSN (Print) (Online)
, 458-463; doi: 10.3329/ajmbr.v2i3.30118 Asian Journal of Medical and Biological Research ISSN 2411-4472 (Print) 2412-5571 (Online) www.ebupress.com/journal/ajmbr Article Management and treatment patterns
More informationCRISIS OF WOMEN DIABETICS IN INDIA : A REVIEW
Int. J. Chem. Sci.: 10(1), 2012, 228-238 ISSN 0972-768X www.sadgurupublications.com CRISIS OF WOMEN DIABETICS IN INDIA : A REVIEW B. G. SOLOMON RAJU *, Y. B. MANJU LATHA, G. LEELA JACOB and A. SHOBA NANDINI
More informationDistinguishing T1D vs. T2D in Childhood: a case report for discussion
Distinguishing T1D vs. T2D in Childhood: a case report for discussion Alba Morales, MD Associate Professor of Pediatrics Division of Pediatric Endocrinology and Diabetes Disclosure I have no financial
More informationGlucose Challenge Test as a Predictor of Type 2 Diabetes
Georgia State University ScholarWorks @ Georgia State University Public Health Theses School of Public Health Fall 1-8-2016 Glucose Challenge Test as a Predictor of Type 2 Diabetes Rahsaan Overton Follow
More informationBoth genetic and environmental factors contribute
Long-Term Improvement in Insulin Sensitivity by Changing Lifestyles of People with Impaired Glucose Tolerance 4-Year Results From the Finnish Diabetes Prevention Study Matti Uusitupa, 1 Virpi Lindi, 1
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationSpecific insulin and proinsulin in normal glucose tolerant first-degree relatives of NIDDM patients
Brazilian Journal of Medical and Biological Research (1999) 32: 67-72 Insulin and proinsulin in first-degree relatives of NIDDM ISSN 1-879X 67 Specific insulin and proinsulin in normal glucose tolerant
More informationLiving Well with Diabetes
Living Well with Diabetes What is diabetes? Diabetes Overview Diabetes is a disorder of the way the body uses food for growth and energy. Most of the food people eat is broken down into glucose, the form
More informationType 2 diabetes is occurring in epidemic proportions
The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging James B. Meigs, 1 Denis C. Muller, 2 David M. Nathan, 3 Deirdre R. Blake,
More informationDevelopment of type 2 diabetes is, to some
Mode of Onset of Type 2 Diabetes from Normal or Impaired Glucose Tolerance Ele Ferrannini, 1 Monica Nannipieri, 1 Ken Williams, 2 Clicerio Gonzales, 3 Steve M. Haffner, 2 and Michael P. Stern 2 Fasting
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationCopyright 2017 by Sea Courses Inc.
Pre-Diabetes: Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical,
More informationResearch Article Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome
Hindawi Diabetes Research Volume 2017, Article ID 5250162, 5 pages https://doi.org/10.1155/2017/5250162 Research Article Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More information2017 Hot topics in cardiometabolism: an interactive update
14-15 July, 2017 - Bogotà, Colombia 2017 Hot topics in cardiometabolism: an interactive update IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicola Napoli Department of Medicine,
More informationThe Second Report of the Expert Panel on Detection,
Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationMaximizing the Role of WIC Nutritionists in Prevention of DM2 among High Risk Clients ESTHER G. SCHUSTER, MS,RD,CDE
Maximizing the Role of WIC Nutritionists in Prevention of DM2 among High Risk Clients ESTHER G. SCHUSTER, MS,RD,CDE Heavy Numbers Surgeon General report: 68% of adults in U. S. are overweight or obese
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationClinical Study 1-Hour OGTT Plasma Glucose as a Marker of Progressive Deterioration of Insulin Secretion and Action in Pregnant Women
Hindawi Publishing Corporation International Journal of Endocrinology Volume 2012, Article ID 460509, 5 pages doi:10.1155/2012/460509 Clinical Study 1-Hour OGTT Plasma Glucose as a Marker of Progressive
More informationGestational Diabetes: Long Term Metabolic Consequences. Outline 5/27/2014
Gestational Diabetes: Long Term Metabolic Consequences Gladys (Sandy) Ramos, MD Associate Clinical Professor Maternal Fetal Medicine Outline Population rates of obesity and T2DM Obesity and metabolic syndrome
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationAssociation between serum IGF-1 and diabetes mellitus among US adults
Diabetes Care Publish Ahead of Print, published online July 16, 2010 Association between serum IGF-1 and diabetes mellitus among US adults Running title: Serum IGF-1 and diabetes mellitus Srinivas Teppala
More informationBariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
More informationIntroduction ORIGINAL RESEARCH. Bilal A. Omar 1, Giovanni Pacini 2 & Bo Ahren 1. Abstract
ORIGINAL RESEARCH Physiological Reports ISSN 2051-817X Impact of glucose dosing regimens on modeling of glucose tolerance and b-cell function by intravenous glucose tolerance test in diet-induced obese
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationOriginal Article Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program
Original Article Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program John M. Lachin, 1 Costas A. Christophi, 1 Sharon L. Edelstein, 1 David
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationImpact of Hemoglobin A1c Screening and Brief Intervention in a Medicare Population
Impact of Hemoglobin A1c Screening and Brief Intervention in a Medicare Population Mary Jo Quinn DNP, ARNP-C, ACHPN Susan Schaffer PhD, ARNP, FNP-BC University of Florida College of Nursing, Gainesville,
More informationPregnancy outcomes in Korean women with diabetes
Pregnancy outcomes in Korean women with diabetes Sung-Hoon Kim Department of Medicine, Cheil General Hospital & Women s Healthcare Center, Dankook University College of Medicine, Seoul, Korea Conflict
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationEffect of Various Degrees of Maternal Hyperglycemia on Fetal Outcome
ORIGINAL ARTICLE Effect of Various Degrees of Maternal Hyperglycemia on Fetal Outcome ABSTRACT Shagufta Tahir, Shaheen Zafar, Savita Thontia Objective Study design Place & Duration of study Methodology
More informationManaging Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More informationFailure of β-cell function for compensate variation in insulin sensitivity in hypomagnesemic subjects
Magnesium Research 2009; 22 (3): 151-6 ORIGINAL ARTICLE Failure of β-cell function for compensate variation in insulin sensitivity in hypomagnesemic subjects Luis E. Simental-Mendía, Martha Rodríguez-Morán,
More information